Cytocom (CBLI) Income Statement

Click line-items for a historical chart and %

Grant and contract
Sales Revenue, Net, Total
Research and development	1.1M
General and administrative
Total operating expenses	1.86M
LOSS FROM OPERATIONS	-714.13K
Interest income
Other income
Other expense
Change in value of warrant liability
Total other (income)/expense	1.85M
NET INCOME/(LOSS)	1.14M
LOSS ATTRIBUTABLE TO NONCONTROLLING INTERESTS	-2.14K
NET INCOME/(LOSS) ATTRIBUTABLE TO CLEVELAND BIOLABS, INC.	1.14M
NET INCOME/(LOSS) AVAILABLE TO COMMON SHAREHOLDERS PER SHARE OF COMMON STOCK BASIC (in dollars per share)
NET INCOME/(LOSS) AVAILABLE TO COMMON SHAREHOLDERS PER SHARE OF COMMON STOCK DILUTED (in dollars per share)
WEIGHTED AVERAGE NUMBER OF SHARES USED IN CALCULATING NET INCOME/(LOSS) PER SHARE, BASIC (in shares)
WEIGHTED AVERAGE NUMBER OF SHARES USED IN CALCULATING NET INCOME/(LOSS) PER SHARE, DILUTED (in shares)

Entities mentioned with CBLI

View All Entities